MEDIA

PUBLICATIONS

2019 Sep
Pridopidine Protects Neurons from Mutant-Huntingtin Toxicity via the Sigma-1 Receptor.
Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA.
Neurobiology disease
Link: https://www.ncbi.nlm.nih.gov/pubmed/31108174
2019 May 16
Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease
Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA.Frontiers in Cellular Neuroscience
Link: https://www.ncbi.nlm.nih.gov/pubmed/31156395
2019 Mar 1
Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model
Ariel Ionescu, Tal Gradus, Topaz Altman, Roy Maimon, Noi Saraf Avraham, Michal Geva, Michael Hayden, Eran Perlson.
Cell Death & Disease
Link: https://www.ncbi.nlm.nih.gov/pubmed/30824685

2019 Feb 12
Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
Veronica Francardo, Michal Geva, Francesco Bez, Quentin Denis, Lilach Steiner, Michael R. Hayden, M. Angela Cenci.
Neurotherapeutics
Link: https://www.ncbi.nlm.nih.gov/pubmed/30756361

2018 Dec 27
Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.
Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, Hayden M, Bezprozvanny I.
Neurobiology Disease
Link: https://www.ncbi.nlm.nih.gov/pubmed/30594810

2018 Dec 21
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.
Movement Disorder Societ
Link: https://www.ncbi.nlm.nih.gov/pubmed/30575996

2018 May 21
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR.
Molecular Neurodegeneration
Link: https://www.ncbi.nlm.nih.gov/pubmed/29783994

2017 Dec 7
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA.
Journal of Clinical Investigation
Link: https://www.ncbi.nlm.nih.gov/pubmed/29212949

2017 Jan
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I.
Neurobiol Disease
Link: https://www.ncbi.nlm.nih.gov/pubmed/27818324
2016 Sep 15
Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR.
Human molecular genetics
Link: https://www.ncbi.nlm.nih.gov/pubmed/27466197

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General